Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Ira R. Katz |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases / Daniel Weintraub en Psychiatric Clinics of North America, Año 2005 - Vol. 28 No. 4 (Diciembre)
[artículo]
Título : Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases : evidence about efficacy and safety Tipo de documento: texto impreso Autores: Daniel Weintraub, Autor ; Ira R. Katz, Autor Fecha de publicación: 2020 Artículo en la página: pp. 941-983 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agentes antipsicóticos, Enfermedades neurodegenerativas, Agitación psicomotora, Trastornos psicóticos. Resumen: Despite a significant body of research in this area, there are critical gaps in the evidence base on the treatment of the psychotic and behavioral symptoms associated with Alzheimer's disease and vascular dementia. This problem has been exacerbated by recent FDA warnings on the risks of increased CVAEs and mortality with atypical antipsychotic treatment, without the release of the scientific evidence on which these warnings are based. Link: ./index.php?lvl=notice_display&id=24642
in Psychiatric Clinics of North America > Año 2005 - Vol. 28 No. 4 (Diciembre) . - pp. 941-983[artículo] Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases : evidence about efficacy and safety [texto impreso] / Daniel Weintraub, Autor ; Ira R. Katz, Autor . - 2020 . - pp. 941-983.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2005 - Vol. 28 No. 4 (Diciembre) . - pp. 941-983
Palabras clave: Agentes antipsicóticos, Enfermedades neurodegenerativas, Agitación psicomotora, Trastornos psicóticos. Resumen: Despite a significant body of research in this area, there are critical gaps in the evidence base on the treatment of the psychotic and behavioral symptoms associated with Alzheimer's disease and vascular dementia. This problem has been exacerbated by recent FDA warnings on the risks of increased CVAEs and mortality with atypical antipsychotic treatment, without the release of the scientific evidence on which these warnings are based. Link: ./index.php?lvl=notice_display&id=24642